Re: USA ZHCLF investors
in response to
by
posted on
Oct 30, 2022 06:27AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
RVXOT:
"From Zenith Capital Corp. MD&A:
“As at July 31, 2022, we hold all 75,202,620 royalty preferred shares of Resverlogix. We, as the sole holder of the royalty preferred shares of Resverlogix, are entitled to dividends in the amount of 6-12% of Resverlogix’s Net Revenue, if any"
Presumably, this would only apply to "ZHCLF" shares trading on the OTC market. It would not apply to Zenith shares acquired directly from Zenith post SPINCO 2013.
Would it be a problem distinguishing between the two sets of Zenith shares when it comes to issuing dividends?
Koo